Tonix Pharmaceuticals Holding Corp (TPM0)
XDUS 
Summary
TPM0 Chart
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals Q2 Earnings Call Highlights
Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.
Tonix Pharmaceuticals Holding Corp (TPM0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tonix Pharmaceuticals Holding Corp ever had a stock split?
Tonix Pharmaceuticals Holding Corp Profile
| Biotechnology Industry | Healthcare Sector | Seth Lederman CEO | XDUS Exchange | US8902608392 ISIN |
| US Country | 142 Employees | - Last Dividend | 5 Feb 2025 Last Split | 10 May 2012 IPO Date |
Overview
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company dedicated to the discovery, acquisition, development, and licensing of therapeutics and diagnostics aimed at treating and preventing human diseases and alleviating suffering. Since its inception in 2007, Tonix Pharmaceuticals has been headquartered in Chatham, New Jersey. Its extensive portfolio spans immunology, rare diseases, infectious diseases, and central nervous system (CNS) product candidates, demonstrating a diverse approach to addressing critical areas of medicine.
Products and Services
- TNX-1500: A humanized monoclonal antibody targeting CD40-ligand, TNX-1500 is under development for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases within the company's immunology portfolio.
- TNX-2900: Designed for the treatment of Prader-Willi syndrome, TNX-2900 represents Tonix Pharmaceuticals' commitment to addressing rare diseases with significant unmet medical needs.
- TNX-801: As part of the infectious disease pipeline, TNX-801 is a vaccine aimed at preventing smallpox and monkeypox, showcasing the company’s efforts in combating emerging and re-emerging infectious diseases.
- TNX-1840 and TNX-1850: These live virus vaccines are based on the company's recombinant pox vaccine (RPV) platform and are in development for COVID-19, reflecting Tonix Pharmaceuticals’ adaptation to current global health challenges.
- TNX-3500: A small molecule antiviral drug, TNX-3500 is aimed at treating acute COVID-19, further contributing to the company’s infectious disease portfolio.
- TNX-102 SL: This small molecule drug serves dual purposes; it is in mid-Phase 3 development for the management of fibromyalgia and also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. This showcases the company's innovative approach in using a single molecule to target different indications.
- TNX-1900: In development for the prevention of migraine headache, TNX-1900 is part of the CNS portfolio, targeting the significant burden of neurological diseases.
- TNX-1300: A biologic designed to treat cocaine intoxication, illustrating Tonix Pharmaceuticals' dedication to addressing addiction and its complications.
